Rev-erb-α regulates atrophy-related genes to control skeletal muscle mass.
Alicia Mayeuf-LouchartQuentin ThorelStéphane DelhayeJustine BeauchampChristian DuhemAnne DanckaertSteve LancelBenoit PourcetEstelle WoldtAlexis BoulinguiezLise FerriMathilde ZecchinBart StaelsYasmine SebtiHélène DuezPublished in: Scientific reports (2017)
The nuclear receptor Rev-erb-α modulates hepatic lipid and glucose metabolism, adipogenesis and thermogenesis. We have previously demonstrated that Rev-erb-α is also an important regulator of skeletal muscle mitochondrial biogenesis and function, and autophagy. As such, Rev-erb-α over-expression in skeletal muscle or its pharmacological activation improved mitochondrial respiration and enhanced exercise capacity. Here, in gain- and loss-of function studies, we show that Rev-erb-α also controls muscle mass. Rev-erb-α-deficiency in skeletal muscle leads to increased expression of the atrophy-related genes (atrogenes), associated with reduced muscle mass and decreased fiber size. By contrast, in vivo and in vitro Rev-erb-α over-expression results in reduced atrogenes expression and increased fiber size. Finally, Rev-erb-α pharmacological activation blocks dexamethasone-induced upregulation of atrogenes and muscle atrophy. This study identifies Rev-erb-α as a promising pharmacological target to preserve muscle mass.
Keyphrases
- skeletal muscle
- poor prognosis
- insulin resistance
- oxidative stress
- binding protein
- adipose tissue
- metabolic syndrome
- magnetic resonance
- cell death
- magnetic resonance imaging
- low dose
- signaling pathway
- type diabetes
- dna methylation
- genome wide
- endoplasmic reticulum stress
- diabetic rats
- contrast enhanced
- smoking cessation
- replacement therapy
- case control